Table S1 - Adherence as a Predictor of the Development of Class-Specific Resistance Mutations: The Swiss HIV Cohort Study

Development of new mutation by adherence level and drug class for individuals who either started their first antiretroviral therapy ever or who started a new class of ART and who had a prior on-treatment genotypic test result available (PI/r: n= 124; NNRTI: n= 111). (DOCX)

本数据集基于治疗依从性水平与所用药物类别，针对以下两类个体分析新突变的发生情况：一类为首次接受抗反转录病毒治疗（antiretroviral therapy, ART）的个体，另一类为启动新类别抗反转录病毒治疗且具备既往治疗期间基因型检测结果的人群；其中增效蛋白酶抑制剂（PI/r, ritonavir-boosted protease inhibitor）组共124例，非核苷类反转录酶抑制剂（NNRTI, non-nucleoside reverse transcriptase inhibitor）组共111例。（DOCX）